Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by (1,019)

Items 901–1,000 of 1,019

1. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
   Run‐Cong Nie, Fo‐Ping Chen, Shuqiang Yuan, Ying-Shan Luo, Shi Chen, Yongming Chen, Xiao‐Jiang Chen, Ying-Bo Chen, Yuanfang Li, Zhiwei Zhou · 2018 · European Journal of Cancer
2. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis
   Fausto Petrelli, Antonio Ghidini, Mary Cabiddu, Gianluca Tomasello, Agostina De Stefani, Lorenza Bruschieri, Elisabetta Vitali, Mara Ghilardi, Karen Borgonovo, Sandro Barni et al. · 2018 · Lung Cancer
3. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
   Chengdi Wang, Wenliang Qiao, Yuting Jiang, Min Zhu, Jun Shao, Pengwei Ren, Dan Liu, Weimin Li · 2019 · Cancer Medicine
4. Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
   Antonio Sica, Valentina Guarneri, Alessandra Gennari · 2019 · Cell Stress
5. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
   Gernot Wagner, Hannah Karolina Stollenwerk, Irma Klerings, Martin Pecherstorfer, Gerald Gartlehner, Josef Singer · 2020 · OncoImmunology
6. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review
   Paz J. Vellanki, Flora A. Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu, Hong Zhao, Jiang Liu, Grant A. Howe, Jian Wang et al. · 2021 · Clinical Cancer Research
7. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy
   Juan Ruiz Bañobre, María Carmen Areses Manrique, Joaquín Mosquera, Alexandra Cortegoso, Francisco J. Afonso-Afonso, N. de Dios Álvarez, Natalia Fernández Núñez, Cristina Azpitarte-Raposeiras, Margarita Amenedo, Lucía Santomé et al. · 2019 · Translational Lung Cancer Research
8. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
   Seo-Young Lee, Hyo Sup Shim, Beung‐Chul Ahn, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong · 2021 · Cancer Immunology Immunotherapy
9. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
   Vincent Lemaire, Colby S. Shemesh, Anand Rotte · 2021 · Journal of Experimental & Clinical Cancer Research
10. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
    Takshveer Singh, Mortaza Fatehi Hassanabad, Ali Fatehi Hassanabad · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
11. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis
    Xianjing Chu, Lishui Niu, Gang Xiao, Haiqin Peng, Fuxing Deng, Zhiyuan Liu, Honghua Wu, Lei Yang, Zhuguilong Tan, Zhanzhan Li et al. · 2022 · Frontiers in Immunology
12. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing–Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non–Small-Cell Lung Cancer in the United States
    Denise Zou, Weicheng Ye, Lisa M. Hess, Naleen Raj Bhandari, Amine Ale-Ali, Jacinda Foster, Peter Quon, Mack Harris · 2022 · Journal of Molecular Diagnostics
13. Repurposing nitric oxide donating drugs in cancer therapy through immune modulation
    Chung-Yen Li, Gangga Anuraga, Chih‐Peng Chang, Tzu-Yang Weng, Hui‐Ping Hsu, Hoang Dang Khoa Ta, Pei‐Fang Su, Pin-Hsuan Chiu, Shiang-Jie Yang, Feng‐Wei Chen et al. · 2023 · Journal of Experimental & Clinical Cancer Research
14. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
    Lingzhi Hong, Muhammad Aminu, Shenduo Li, Xuetao Lu, Milena Petranović, Maliazurina Binti Saad, Pingjun Chen, Kang Qin, Susan Varghese, Waree Rinsurongkawong et al. · 2023 · Nature Communications
15. Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
    Molly Siu Ching Li, Kevin K. S. Mok, Tony S.K. Mok · 2023 · Annals of Translational Medicine
16. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
    Wan‐Teck Lim, Hsiang‐Fong Kao, Lisda Suteja, Constance H. Li, Hong Sheng Quah, Daniel S.W. Tan, Sze Huey Tan, Eng-Huat Tan, Wan-Ling Tan, Justina Nadia Lee et al. · 2023 · Nature Communications
17. Targeted Therapeutic Strategies for the Treatment of Cancer
    Benjamin Victoir, Cécile Croix, Fabrice Gouilleux, Gildas Prié · 2024 · Cancers
18. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)
    Maryam Abdipourbozorgbaghi, Adrienne Vancura, Ramin Radpour, Simon Haefliger · 2024 · British Journal of Cancer
19. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
    Xavier Orcutt, Kan Chen, Ronac Mamtani, Qi Long, Ravi Bharat Parikh · 2025 · Nature Medicine
20. Clinical development of immuno-oncology therapeutics
    Jianxin Wang, Qi Chen, qiang Shan, Tingbo Liang, Patrick M. Forde, Lei Zheng · 2025 · Cancer Letters
21. Frontline immunotherapy for NSCLC — the tale of the tail
    Anne C. Chiang, Roy S. Herbst · 2020 · Nature Reviews Clinical Oncology
22. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist
    Alexandra Lewis, Jamie E. Chaft, Monica Girotra, Gregory W. Fischer · 2020 · British Journal of Anaesthesia
23. Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
    Maria Togo, Takehiko Yokobori, Kimihiro Shimizu, Tadashi Handa, Kyoichi Kaira, Takaaki Sano, Mariko Tsukagoshi, Tetsuya Higuchi, Satoshi Yokoo, Ken Shirabe et al. · 2020 · British Journal of Cancer
24. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
    Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki et al. · 2020 · Cancers
25. New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
    Ramon Andrade de Mello, Nathália Moisés Neves, Hakaru Tadokoro, Giovanna Araújo Amaral, Pedro Castelo‐Branco, Victor André de Almeida Zia · 2020 · Journal of Clinical Medicine
26. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
    Elizabeth Dudnik, Samuel A. Kareff, Mor Tal Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem et al. · 2021 · Journal for ImmunoTherapy of Cancer
27. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
    Shinkichi Takamori, Kazuki Takada, Mototsugu Shimokawa, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Masafumi Yamaguchi, Tatsuro Okamoto, Yasuto Yoneshima et al. · 2020 · Lung Cancer
28. Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives
    Rafieh Bagherifar, Seyed Hossein Kiaie, Zahra Hatami, Armin Ahmadi, Abdolvahid Sadeghnejad, Behzad Baradaran, Reza Jafari, Yousef Javadzadeh · 2021 · Journal of Nanobiotechnology
29. Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Qilin Zhang, Pan Wu, Xucheng He, Yufeng Ding, Yamin Shu · 2021 · Frontiers in Oncology
30. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
    Kenneth L. Kehl, David M. Zahrieh, Ping Yang, Shauna L. Hillman, Angelina D. Tan, Jacob M. Sands, Geoffrey R. Oxnard, Erin Alexis Gillaspie, Dennis A. Wigle, Shakun M. Malik et al. · 2022 · JAMA Oncology
31. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
    Ankita Mitra, Anoop Kumar, Nitin Purushottam Amdare, Rajiv Pathak · 2024 · Biology
32. Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
    Anna Sophie Berghoff, Beatríz Bellosillo, Christophe Caux, Adrianus Johannes De Langen, Julien Mazières, Nicola Normanno, Matthias Preusser, Mariano Provencio, Federico Rojo, Jürgen Wolf et al. · 2019 · ESMO Open
33. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
    Petros D. Grivas, Bradley J. Monk, Daniel Peter Petrylak, Martin Reck, Grace Foley, Silke Guenther, Dan Hennessy, Constantin Makris, Markus Hermann Moehler · 2019 · Targeted Oncology
34. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer
    Ashley Evan Ross, Paula J. Hurley, Phuoc Tho Tran, Steven P. Rowe, Benjamin Benzon, Tanya O’ Neal, Carolyn G. Chapman, Rana Harb, Yelena Milman, Bruce J. Trock et al. · 2019 · Prostate Cancer and Prostatic Diseases
35. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
    Nicholas Gravbrot, Kacy Gilbert-Gard, Paras P Mehta, Yarah Ghotmi, Madhulika Banerjee, Christopher M. Mazis, Srinath Sundararajan · 2019 · Antibodies
36. 5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients
    Min Zhang, Yibo Fan, Xiaofang Che, Kezuo Hou, Chaoxu Zhang, Ce Li, Ti Wen, Shuo Wang, Yu Cheng, Yunpeng Liu et al. · 2020 · Frontiers in Oncology
37. Supplementation of l ‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
    Yusuke Satoh, Hitoshi Kotani, Yuichi Iida, Takahito Taniura, Yoshitomo Notsu, Mamoru Harada · 2020 · Cancer Science
38. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
    Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo, Jorgina Serra-López, Geòrgia Anguera, Pablo Gallardo, Ivana Sullivan, A. Barba Joaquín, L.P. del Carpio, Agustí Barnadas et al. · 2020 · Frontiers in Oncology
39. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
    Zhen Zhang, Hao‐Xiang Wu, Wu‐Hao Lin, Zixian Wang, Lu-Ping Yang, Zhao-Lei Zeng, Hui Luo · 2021 · BMC Medicine
40. Lung cancer stigma and depression: validation of the lung cancer stigma inventory
    Ostroff, Jamie S., Riley, Kristen E., Shen, Megan J., Atkinson, Thomas M., Williamson, Timothy J., Hamann, Heidi A. · 2019 · Psycho-Oncology
41. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
    Shiraishi, Yoshimasa, Kishimoto, Junji, Sugawara, Shunichi, Mizutani, Hideaki, Daga, Haruko, Azuma, Koichi, Matsumoto, Hirotaka, Hataji, Osamu, Nishino, Kazumi, Mori, Masahide et al. · 2024 · JAMA Oncology
42. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
    Ying Cheng, Li Zhang, Jie Hu, Donglin Wang, Chengping Hu, Jianying Zhou, Lin Wu, Lejie Cao, Jiwei Liu, Helong Zhang et al. · 2021 · JTO Clinical and Research Reports
43. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
    Chang Gon Kim, Gamin Kim, Kyung Hwan Kim, Seyeon Park, Sunhye Shin, Dahee Yeo, Hyo Sup Shim, Hong In Yoon, Sung Yong Park, Sang‐Jun Ha et al. · 2021 · Journal for ImmunoTherapy of Cancer
44. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
    David Joseph Benjamin, Alexander Xu, Mark Peter Lythgoe, Vinay K. Prasad · 2022 · JAMA Network Open
45. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases
    Eric J. Lehrer, Roman O. Kowalchuk, Jason Gurewitz, Kenneth Bernstein, Douglas S Kondziolka, Ajay Niranjan, Zhishuo Wei, L. Dade Lunsford, Kareem Fakhoury, Chad G. Rusthoven et al. · 2023 · International Journal of Radiation Oncology*Biology*Physics
46. Additivity predicts the efficacy of most approved combination therapies for advanced cancer
    Haeun Hwangbo, Sarah C. Patterson, Andy Dai, Deborah Plana, Adam Christopher Palmer · 2023 · Nature Cancer
47. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
    Hossein Borghaei, Kenneth John O'Byrne, Luis G Paz-Ares, T-E. Ciuleanu, Xiaochu Yu, Adam Płużański, Adnan M. Nagrial, Libor Havel, Rubén Dario Kowalyszyn, Clarisse Audigier-Valette et al. · 2023 · ESMO Open
48. Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
    Racheli Birnboim-Perach, Itai Benhar · 2024 · International Journal of Biological Sciences
49. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study
    Zhe Huang, Abdoulaye Karaboué, Liang Zeng, Adrien Lecoeuvre, Lemeng Zhang, Xiaomei Li, Haoyue Qin, Gabrielle Danino, Feng Yang, Marie-Sara Malin et al. · 2025 · EBioMedicine
50. Immunotherapy in the Asiatic population: any differences from Caucasian population?
    Lun-Xi Peng, Yi-Long Lung Cancer Wu · 2018 · Journal of Thoracic Disease
51. “Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway
    Sarah A. Best, Kate D. Sutherland · 2018 · Cell Cycle
52. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
    Yael Eshet, Erez N. Baruch, Ronnie Shapira‐Frommer, Yael Steinberg‐Silman, Teodor Kuznetsov, Guy Ben‐Betzalel, Sameh Daher, Iris Gluck, Nethanel Asher, Sara Apter et al. · 2018 · Cancer Immunology Research
53. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review
    Meghan E. Sise, Harish Shanthanu Seethapathy, Kerry Lynn Reynolds · 2019 · The Oncologist
54. Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
    Martin Reck, Hossein Borghaei, Kenneth John O'Byrne · 2019 · Future Oncology
55. Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
    Ning Wan, Tian‐tian Zhang, Si‐hua Hua, Zi‐luo Lu, Bo Ji, Lixia Li, Liqing Lu, Wenjie Huang, Jie Jiang, Jian Li · 2020 · Cancer Medicine
56. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor
    Chunyan Xue, Yun Xu, Wenfeng Ye, Quanqin Xie, Hongyan Gao, Bin Xu, Dachuan Zhang, Jingting Jiang · 2020 · Gynecologic Oncology
57. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC
    Daphne W. Dumoulin, Sabine Visser, Robin Cornelissen, Teun van Gelder, Johan Vansteenkiste, Jan H. von der Thüsen, Joachim G.J.V. Aerts · 2020 · Journal of Thoracic Oncology
58. Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors
    Taisuke Isono, Naho Kagiyama, Kenji Takano, Chiaki Hosoda, Takashi Nishida, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Youtaro Takaku, Kazuyoshi Kurashima et al. · 2020 · Thoracic Cancer
59. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis
    Yin Yang, Lei Deng, Yufan Yang, Tao Zhang, Yuqi Wu, Lühua Wang, Nan Bi · 2021 · Clinical Lung Cancer
60. Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
    Qiao Liu, Zhen Zhou, Xiaohui Zeng, Chongqing Tan · 2021 · Frontiers in Pharmacology
61. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
    Lucia Parlati, Anaïs Vallet‐Pichard, Rui Batista, Alain Hernvann, Philippe Sogni, Stanislas Pol, Vincent Olivier Mallet · 2018 · Journal of Hepatology
62. Checkpoint immunotherapy in pediatrics: here, gone, and back again
    Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book
63. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
    Xingxiang Pu, Lin Wu, Dan Su, Weimin Mao, Bingliang Fang · 2018 · BMC Cancer
64. Blood Predictive Biomarkers for Patients With Non–small-cell Lung Cancer Associated With Clinical Response to Nivolumab
    María Teresa Agulló-Ortuño, Óscar Gómez-Martín, Santiago Ponce, L. Iglesias, Laura Ojeda, Irene Ferrer, Inmaculada García‐Ruíz, Luis G Paz-Ares, Virginia Pardo · 2019 · Clinical Lung Cancer
65. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer
    Tamjeed Ahmed, Thomas William Lycan, Andy Shipe Dothard, Paul D. Ehrlichman, Jimmy Ruiz, Michael K Farris, Ümit Topaloĝlu, Beverly J. Levine, Stefan C. Grant, Heidi D. Klepin et al. · 2020 · Clinical Lung Cancer
66. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018
    Gabriel E. Molina, Leyre Zubiri, Justine Vanessa Cohen, Sienna Durbin, Laura A. Petrillo, Ian Matthew Allen, Yonina R. Murciano‐Goroff, Michael Lawrence Dougan, Molly Fisher Thomas, Alexander T. Faje et al. · 2021 · The Oncologist
67. Tumour neoantigen mimicry by microbial species in cancer immunotherapy
    Maximilian Boesch, Florent Baty, Sacha I. Rothschild, M. Tamm, Markus Joerger, Martin Früh, Martin Hugo Brutsche · 2021 · British Journal of Cancer
68. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
    Filippo Gustavo Dall’Olio, Diletta Calabrò, Nicole Conci, Giulia Argalia, Paola Valeria Marchese, Francesca Fabbri, Benedetta Fragomeno, Dalia Ricci, Stefano Fanti, Valentina Ambrosini et al. · 2021 · European Journal of Cancer
69. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer
    Ilke Tunali, Yan Qin Tan, Jhanelle E Gray, Evangelia Katsoulakis, Steven A. Eschrich, James Joseph Saller, Hugo J.W.L. Aerts, Theresa A. Boyle, Jin Qi, Albert Güveniş et al. · 2021 · JNCI Cancer Spectrum
70. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data
    Tigran Makunts, Ila Maewal Saunders, Isaac V. Cohen, Mengxing Li, Talar Moumedjian, Masara A. Issa, Keith Burkhart, Peter Lee, Sandip Pravin Patel, Ruben A Abagyan · 2021 · Scientific Reports
71. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
    Doreen Anuli Ezeife, Eldon Spackman, Rosalyn Anne Juergens, Janessa J. Laskin, Jason Scott Agulnik, Desirée Hao, Scott Andrew Laurie, Jennifer H. Law, Lisa W. Le, Lesli Ann Kiedrowski et al. · 2022 · Therapeutic Advances in Medical Oncology
72. An update on treatment of penile cancer
    Juskaran S. Chadha, Jad Chahoud, Philippe E. Spiess · 2022 · Therapeutic Advances in Medical Oncology
73. Nanomedicine in Lung Cancer Immunotherapy
    Mohammad Doroudian, Saba Zanganeh, Elham Abbasgholinejad, Seamas C. Donnelly · 2023 · Frontiers in Bioengineering and Biotechnology
74. Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
    Dorine de Jong, Jeeban P. Das, Hong Ma, Jacienta Pailey Valiplackal, Conor M. Prendergast, Tina Roa, Brian Braumuller, Aileen Deng, Laurent Dercle, Randy Yeh et al. · 2023 · Cancers
75. Recent advances in lung cancer research: unravelling the future of treatment
    Luca Bertolaccini, Monica Casiraghi, Clarissa Uslenghi, Sebastiano Maiorca, Lorenzo Spaggiari · 2024 · Updates in Surgery
76. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
    Ying L. Liu, Dmitriy Zamarin · 2018 · Current Oncology Reports
77. The innate immune architecture of lung tumors and its implication in disease progression
    Simon Milette, Pierre Fiset, Logan A. Walsh, Jonathan David Spicer, Daniela F. Quail · 2019 · The Journal of Pathology
78. Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
    Angela Alama, Simona Coco, Carlo Genova, Giovanni Rossi, Vincenzo Fontana, Marco Tagliamento, Maria Giovanna Dal Bello, Alessandra Rosa, Simona Boccardo, Erika Rijavec et al. · 2019 · Journal of Clinical Medicine
79. Tumor Mutational Burden Is Site Specific in Non–Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases
    Matthew K. Stein, Manjari K Pandey, Joanne Xiu, Hongseok Tae, Jeffrey J. Swensen, Sandeep Mittal, Andrew Jacob Brenner, Wolfgang Michael Korn, Amy B. Heimberger, Mike G. Martin · 2019 · JCO Precision Oncology
80. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
    Carmine Carbone, Geny Piro, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Miriam Grazia Ferrara, Sara Pilotto, Michèle Milella, Giovanni Cammarota, Antonio Gasbarrini et al. · 2019 · Mediators of Inflammation
81. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice
    Laurie E. Steffen McLouth, Thomas William Lycan, Beverly J. Levine, Jennifer Gabbard, Jimmy Ruiz, Michael K Farris, Stefan C. Grant, Nicholas M. Pajewski, Kathryn E. Weaver, William Jeffrey Petty · 2019 · Clinical Lung Cancer
82. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
    Shira Sherman, Ofer Rotem, Tzippy Shochat, Alona Zer, Assaf Moore, Elizabeth Dudnik · 2020 · Lung Cancer
83. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
    José Carlos Benítez, Jordi Remón, Benjamin Besse · 2020 · Clinical Cancer Research
84. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
    Joshua T. Burgess, Maddison Rose, Didier Boucher, Jennifer Plowman, Christopher Molloy, Mark A. Fisher, Connor Gerard O’Leary, Derek J. Richard, Kenneth John O'Byrne, Emma Bolderson · 2020 · Frontiers in Oncology
85. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy
    Romain‐David Seban, Jean‐Baptiste Assié, Etienne Giroux Leprieur, Marie-Ange Massiani, G. Bonardel, CHRISTOS CHOUAID, Nicolas Deleval, Capucine Richard, Laura Mezquita, Nicolas Girard et al. · 2021 · Lung Cancer
86. Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials
    Manting Wang, Hengrui Liang, Wei Wang, Shen Zhao, Xiuyu Cai, Yi Zhao, Caichen Li, Bo Cheng, Shan Xiong, Jianfu Li et al. · 2020 · Cancer
87. Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies
    Sanna Iivanainen, Jussi Ekström, Henri Virtanen, Vesa V Kataja, Jussi Pekka Koivunen · 2021 · BMC Medical Informatics and Decision Making
88. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
    Paul van der Leest, Birgitta I. Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja ter Elst, Wim Timens, Harry J.M. Groen, Léon C.L.T. van Kempen, T. Jeroen N. Hiltermann et al. · 2021 · Molecular Oncology
89. Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
    Muhammad Furqan, Taher Abu Hejleh, Laura M. Stephens, Stacey M. Hartwig, Sarah L. Mott, Casey F. Pulliam, Michael S. Petronek, John B. Henrich, Melissa A. Fath, Jon C. D. Houtman et al. · 2022 · Redox Biology
90. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden
    Mariano Provencio, Ana Laura Ortega Granados, Juan Coves-Sarto, Virginia Calvo, Raquel Marse Fabregat, Manuel Dómine, María Guirado, Enric Carcereny, Natalia Fernández, Ruth Álvarez et al. · 2022 · JAMA Oncology
91. Endocrine side effects of immune checkpoint inhibitors
    Zulma Cardona, Jeffrey Alan Sosman, Sunandana Chandra, Wenyu Huang · 2023 · Frontiers in Endocrinology
92. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
    Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Hidetoshi Hayashi, Koichi Azuma, Satoshi Hara, Seiji Niho, Ryo Morita et al. · 2024 · The Lancet Respiratory Medicine
93. Liposomes-enabled cancer chemoimmunotherapy
    Lele Zhang, Jiangpei Shi, Mao‐Hua Zhu, Yanhu Huang, Qin Lu, Peng Sun, Hongzhuan Chen, Xing Ping Lai, Chao Fang · 2024 · Biomaterials
94. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis
    Corey Christian Foster, David Jonathan Sher, Chad G. Rusthoven, Vivek Verma, Michael T. Spiotto, Ralph R. Weichselbaum, Matthew Koshy · 2019 · Radiation Oncology
95. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
    Hongge Liang, Mengzhao Wang · 2019 · Cancer Management and Research
96. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, Seigo Ishii, Katsuya Hirano, Hirotaka Matsumoto, Yasushi Fukuda, Toshihide Yokoyama, Ryota Kominami, Daichi Fujimoto et al. · 2019 · Investigational New Drugs
97. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application
    Guangyuan Hu, Wei Tu, Yang Liu, Guang Peng, Lin Yang · 2020 · Cancer Letters
98. A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions
    Yukari Kobayashi, Yoshihiro Kushihara, Noriyuki Saito, Shigeo Yamaguchi, Kazuhiro Kakimi · 2020 · Cancer Science
99. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
    Rajesh M. Valanparambil, Jennifer Wilkinson Carlisle, Susanne L. Linderman, Akil Akhtar, Ralph Linwood Millett, Lilin Lai, Andrés Chang, Ashley A. McCook‐Veal, Jeffrey M. Switchenko, Tahseen H. Nasti et al. · 2022 · Journal of Clinical Oncology
100. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis
     Kaili Yang, Jiarui Li, Chunmei Bai, Zhao Sun, Lin Zhao · 2020 · Frontiers in Oncology